| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA355: Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation |
|
Medicine details |
|
| Medicine name | edoxaban (Lixiana®) |
| Formulation | 15 mg, 30 mg and 60 mg film-coated tablet |
| Reference number | 673 |
| Indication | Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA) |
| Company | Daiichi Sankyo UK Ltd |
| BNF chapter | Cardiovascular system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 26/05/2015 |
| NICE guidance | |